Human Papillomavirus (HPV) And Cytomegalovirus (CMV) Therapeutics Market Size Anticipated To Reach US$ 4.8 Billion With 6.0% CAGR By 2026 | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 3,006.4 million in 2018, and is projected to exhibit a CAGR of 6.0%, during the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2707

Cytomegalovirus (CMV) is also known as Human Herpes Virus 5 (HHV-5). The virus is usually transmitted to the developing fetus and affects both men and women equally at any age. For example, in January 2018, according to the Centers for Disease Control and Prevention (CDC), around 50% adults were suffering from CMV infections in the U.S.

The rising approval of novel therapies is projected to drive the growth of the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market. For instance, in January 2016, Fate Therapeutics Inc. received approval from the U.S. food and Drug Administration (FDA) for its new programmed cellular immunotherapy ProTmune. It is used to prevent acute GvHD (Graft- versus-Host Disease) infection and CMV infection.

Browse 37 Market Data Tables and 33 Figures spread through 167 Pages and in-depth TOC on ” Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and  Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026″ 

To know the latest trends and insights related to Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market Press Release, click the link below: https://bit.ly/3dOp6xw

The growth of the human papillomavirus and cytomegalovirus therapeutics market during the forecast period (2018 – 2026) is likely to be attributed to continuous research and development activities for the treatment of HPV and CMV infections. For instance, in May 2014, Atara Biotherapeutics initiated the clinical study of preemptive adoptive CMV-specific T cells (CMVpp65) infusion for prevention of refractory CMV infection in patients. These cells can clear CMV infection and restore antiviral immunity after allogeneic hematopoietic stem cell transplantation.

Moreover, in July 2012, University of Alabama at Birmingham initiated clinical phase II study of quadrivalent HPV recombinant vaccine. It is used for the treatment of HPV (types 6, 11, 16, 18) infections. This study is expected to complete in November 2020. In January 2018, Shire Company received approval from the U.S. Food and Drug Administration (FDA) for its new investigational treatment drug Maribavir (SHP620), used to treat CMV infections.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2707

Key Takeaways of the Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market:

• The global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market is expected to witness a CAGR of 6.0% during the forecast period (2018 – 2026) due to the rising incidence of cervical cancer in the U.S. For example, according to the World Health Organization (WHO) report, around 570,000 women suffer from cervical cancer and around 311,000 women died from cervical cancer across the globe in 2018.
• North America is expected to hold the largest market share for the human papillomavirus (HPV) and cytomegalovirus (CMV) market due to the rising approval activities by the U.S. Food and Drug Administration (FDA). For instance, FDA announced approval of Keytruda (Contains-Pembrolizumab) in June 2018, which is used for the treatment of PD-L1–positive cervical cancer.
• Major players operating in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market are Allergan, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi.

Have a Look at Related Research Insights: